Andrzej Każarnowicz

10.2k total citations · 1 hit paper
14 papers, 578 citations indexed

About

Andrzej Każarnowicz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andrzej Każarnowicz has authored 14 papers receiving a total of 578 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Andrzej Każarnowicz's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer therapeutics and mechanisms (4 papers). Andrzej Każarnowicz is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer therapeutics and mechanisms (4 papers). Andrzej Każarnowicz collaborates with scholars based in Poland, United States and Spain. Andrzej Każarnowicz's co-authors include Martin Reck, H. Depenbrock, György Losonczy, Beatrix Bálint, Rodryg Ramlau, Tudor–Eliade Ciuleanu, Shivani Nanda, Aleksandra Szczęsna, Mark A. Socinski and Nick Thatcher and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Andrzej Każarnowicz

13 papers receiving 564 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Andrzej Każarnowicz

Since Specialization

Citations

This map shows the geographic impact of Andrzej Każarnowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrzej Każarnowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrzej Każarnowicz more than expected).

Fields of papers citing papers by Andrzej Każarnowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrzej Każarnowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrzej Każarnowicz. The network helps show where Andrzej Każarnowicz may publish in the future.

Co-authorship network of co-authors of Andrzej Każarnowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Andrzej Każarnowicz. A scholar is included among the top collaborators of Andrzej Każarnowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrzej Każarnowicz. Andrzej Każarnowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial 2020 ·Annals of Oncology ·Aaron S. Mansfield, Andrzej Każarnowicz, Nina Karaseva, (unknown), Richard de Boer, Zoran Andrić, Martin Reck, Shinji Atagi, Jae‐Seong Lee, Marina Chiara Garassino, Stephen V. Liu, Leora Horn, Xiaoming Wen, Caroleen Quach, Weiguang Yu, Fairooz F. Kabbinavar, Sivuonthanh Lam, S. Morris, Raffaele Califano	126
2	IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC) 2018 ·Annals of Oncology ·Raffaele Califano, Andrzej Każarnowicz, (unknown), (unknown), Stephen V. Liu, Leora Horn, Caroleen Quach, Wei Yu, Fairooz F. Kabbinavar, S. Lam, Aaron S. Mansfield	3
3	Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study 2015 ·Journal of Thoracic Oncology ·Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczęsna, W Szafrański, Rodryg Ramlau, Beatrix Bálint, Andrzej Każarnowicz, Olivier Molinier, H. Depenbrock, Shivani Nanda, Luis Paz‐Ares, Nick Thatcher	1
4	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Nick Thatcher, Fred R. Hirsch, Alexander Luft, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, H. Depenbrock, Shivani Nanda, (unknown), Raffael Kurek, Luis Paz‐Ares, Mark A. Socinski	331
5	Przeżycia chorych na niedrobnokomórkowego raka płuca leczonych napromienianiem w latach 2003–2006 w Samodzielnym Publicznym Zakładzie Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie 2015 ·Nowotwory Journal of Oncology ·(unknown), Monika Rucińska, Andrzej Każarnowicz, Sergiusz Nawrocki	0
6	Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study. 2015 ·Journal of Clinical Oncology ·Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczęsna, W Szafrański, Rodryg Ramlau, Beatrix Bálint, Andrzej Każarnowicz, Olivier Molinier, H. Depenbrock, Shivani Nanda, Luis Paz‐Ares, Nick Thatcher	1
7	TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial 2015 ·Journal for ImmunoTherapy of Cancer ·John Nemunaitis, Zsolt Pápai, H. Léna, György Losonczy, Frédéric Forget, C. Chouaïd, (unknown), Radj Gervais, Christian H. Ottensmeier, J.T. Beck, Andrzej Każarnowicz, Virginie Westeel, D. Debieuvre, Anne Madroszyk, Enriqueta Felip, J.M. Limacher, Élisabeth Quoix	1
8	Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer 2014 ·Lung Cancer ·Corey J. Langer, István Albert, Helen J. Ross, Péter Kovács, L. Johnetta Blakely, Gábor Pajkos, Attila Somfay, Petr Zatloukal, Andrzej Każarnowicz, Mehdi M. Moezi, Marshall T. Schreeder, (unknown), (unknown), Ashutosh Pathak, Mark S. Berger	55
9	TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Élisabeth Quoix, György Losonczy, Frédéric Forget, C. Chouaïd, Zsolt Pápai, R. Gervais, Christian H. Ottensmeier, Aleksandra Szczęsna, Andrzej Każarnowicz, J. Thaddeus Beck, Virginie Westeel, (unknown), G Lacoste, Bérangère Bastien, Céline Halluard, Serge Marchand, J.M. Limacher, H. Léna	2
10	Time, a Phase 2B/3 Study Evaluating Tg4010 in Combination with First Line Therapy in Advanced Non Small Cell Lung Cancer (Nsclc). Phase 2B Results 2014 ·Annals of Oncology ·E. Quoix, György Losonczy, Frédéric Forget, C. Chouaïd, Zsolt Pápai, R. Gervais, Christian H. Ottensmeier, Aleksandra Szczęsna, Andrzej Każarnowicz, J. Thaddeus Beck, Virginie Westeel, Enriqueta Felip, D. Debieuvre, Anne Madroszyk, G Lacoste, Annette Tavernaro, Bérangère Bastien, Tania Palanché, J.M. Limacher, H. Léna	4
11	A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). 2014 ·Journal of Clinical Oncology ·Nick Thatcher, Fred R. Hirsch, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, W Szafrański, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, Luis Paz‐Ares, H. Depenbrock, Shivani Nanda, (unknown), Mark A. Socinski	35
12	A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC) 2013 ·Journal of Thoracic Oncology ·Bonnie S. Glisson, Andrzej Każarnowicz, Kristiaan Nackaerts, Sergey Orlov, Rodryg Ramlau, Benjamin Besse, Manuel Cobo, Hari Menon, Luis Paz-Ares Rodríguez, Yilong Zhang, Min Zhu, Yizhou Jiang, Elwyn Loh, Jennifer Gansert, Sarita Dubey	4
13	[Cardiac tamponade as the first symptom of lung cancer]. 2013 ·PubMed ·Leszek Gromadziński, (unknown), (unknown), Jerzy Górny, (unknown), Andrzej Każarnowicz, Piotr Pruszczyk	1
14	A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). 2011 ·Journal of Clinical Oncology ·Corey J. Langer, István Albert, (unknown), L. Johnetta Blakely, Gábor Pajkos, Petar Petrov, A Somfay, A. Szczęsna, Petr Zatloukal, Andrzej Każarnowicz, (unknown), Marshall T. Schreeder, (unknown), M. S. Berger	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact